



The European Association Medical devices
Notified Bodies

EMA Medical Device awareness session

Notified body perspective
of implementation of the new regulations

Françoise Schlemmer, Team-NB Director
June 22nd 2018 - London

TEAM-NB


◆ Aims:

- ❖ Communication with
 - Industry associations
 - European Commission
 - Competent Authorities
- ❖ Promote technical and ethical standards
- ❖ Participate in improving the legal framework
- ❖ Contribute to harmonization
- ❖ Represent Notified Bodies



TEAM-NB

Members



Code of Conduct V 3.4

- ◆ Mandatory to sign for TEAM-NB members
- ◆ Version 3.4 approved
Available on website : www.team-nb.org

Code of Conduct for Notified Bodies

under Directives

90/385/EEC, 93/42/EEC and 98/79/EC

"Improving implementation of the European CE certification of medical devices through harmonization of quality and competence of Notified Bodies"

Version: 3.4

Date: December 2015

Interpretation of the new regulations

- ◆ Team-NB established working groups from April 2016




- ◆ Aim: formulate an analyse of the new regulations and propose to the members

- ❖ Procedures to be put in place
- ❖ To-do lists
- ❖ ...


to be done to submit application for designation and/or wait for implementing acts

- ➔ **Help members to be designated**
- ➔ **Allow harmonisation**

Team-NB: designation process



- 80% of applications before February 2018
 - 50% for bigger scope of application
 - 50% for same scope of application



- 55% of the members are candidates for IVDR
 - 73% applied before February 2018
 - 27% to apply in 2018

Designation of notified bodies

- ◆ **Notified body designated according to MDR / IVDR before certification of manufacturers**
- ◆ **Steps**
 - ❖ List of codes published in an implementing act - November 2017
 - ❖ Introduction of an application for designation by NBs
 - On November 26th, 2017 at the earliest
 - 80% of the members did it 2017

Designation of notified bodies

◆ Steps (... to be followed)

❖ Joint audit assessment

- April 2018: 3 assessments performed


❖ ...

❖ Conformity assessment bodies designated on NANDO

 **Transparency of the designation process (on-going survey)**

 **All codes to be covered**

Transition period



- ◆ **MDR: From May 26th 2020 to May 2024**
- ◆ **IVDR: From May 26th 2022 to May 2024**
- ◆ **Contract between Manufacturers and NBs**
 - ❖ update to be signed to allow surveillance audits

Transition period

- ◆ **CE mark after "Entry into Application"**
 - ❖ Compliance with MDD or AIMD
 - ❖ No significant change in design and intended purpose
 - ❖ Application of the requirements of the Regulations related to
 - Post-market surveillance, Market surveillance, Vigilance, Registration of economic operators and devices,
 - ❖ NB remains in charge of surveillance

Regulation tools

◆ Commission tools

Under the MDCG supervision

❖ Common specifications

↪ **New instrument to be adopted by implementing acts which manufacturers will need to apply**

❖ Delegated and implementing acts

↪ **instrument to precise regulation articles**

European databank on MD (EUDAMED)

- ◆ **Use of a medical device nomenclature mandatory**
- ◆ **Data to be uploaded to collate and process information regarding MD**
 - ❖ **SRN – single registration number**
 - ❖ **UDI – unique device identifier -> traceability**
 - ❖ **aspects of conformity assessment**
 - ❖ **notified bodies**
 - ❖ **certificates**
 - ❖ **clinical investigations**
 - ❖ **vigilance and market surveillance**

Drug Device Combinations (DDC)

◆ Single integral products not reusable – Article 117

↪ Product is a **pharmaceutical**

❖ Notified Body assess the device part - Annex I

↪ Product **not** CE marked

↪ Notified Body and EMA may need to work out a conformity assessment process for the “reverse consultation” on medical device aspects, through published guidance, including designation code (MDS)

Drug Device Combinations (DDC)

- ◆ **Device incorporating a medicinal product – Rule 14** - medicinal product derived from human blood or human plasma, versus human blood derivatives;
 - ❖ Device part reviewed by a Notified Body for both
 - ✓ the technical documentation and
 - ✓ the QMS
 - ❖ Pharmaceutical part reviewed by EMA or a medicinal products CA

Drug Device Combinations (DDC)

In both case

- ◆ **appropriate interaction in terms of**
 - ❖ consultations during pre-market assessment, and
 - ❖ vigilance activities.

Devices that are systemically absorbed

- ◆ **Device part reviewed by a Notified Body for both**
 - ✓ the technical dossier and
 - ✓ the QMS

- ◆ **Compliance of the device reviewed by EMA or a medicinal products CA on relevant aspects in Annex I Directive 2001/83/EC.**
 - ↪ **Product CE marked**
 - ↪ **Classified in Class III – Rule 21**

Companion diagnostics (*in vitro* MD)

- ◆ Linked with quantitative or qualitative determination of specific markers (biomarker)
- ◆ Draft IFU and Draft Report on Safety and Performance to be provided by NB to MPCA / EMA
- ↪ Classified in class C - Rule 3
- ↪ Classified in class D – Article 48
 - ❖ Article 48 requires short consultation process with either MPCA or EMA before CE marking

Companion diagnostics (*in vitro* MD)

◆ NB shall

- ❖ have procedures for consultation of EMA or a medicinal products CA
- ❖ assess the technical documentation (Annex IX or X)
- ❖ seek a scientific opinion from 1 CA or EMA
- ❖ assess the Quality management system (Annex IX or XI)

↪ **Need to set up of guidance's with participation of NBs**

Contacts : www.team-nb.org

- ◆ **Guy Buijzen** President (guy.buijzen@dekra.com)
- ◆ **Hans Heiner Junker** Vice President (hans-heiner.junker@tuev-sued.de)
- ◆ **Kevin Butcher** Vice President (kevin.butcher@sgs.com)
- ◆ **Corinne Delorme** Secretary (corinne.delorme@lne.fr)
- ◆ **Alexey Shiryaev** Treasure (Alexey.Shiryaev@presafe.com)
- ◆ **Françoise Schlemmer** Director&Secretariat (schlemmer@quasys.com)

Members : *DARE!!*



...making excellence a habit.™



ΕΘΝΙΚΟ ΚΕΝΤΡΟ ΑΞΙΟΛΟΓΗΣΗΣ ΤΗΣ ΠΟΙΟΤΗΤΑΣ & ΤΕΧΝΟΛΟΓΙΑΣ ΣΤΗΝ ΥΓΕΙΑ Α.Ε.
NATIONAL EVALUATION CENTER OF QUALITY & TECHNOLOGY IN HEALTH S.A.

